Conference abstractPublished 23 Jul 2018
Dosimetry and efficacy analysis of 125i radioactive seeds implantation for cervical cancer with pelvic recurrent after radiotherapy
Peking University Third Hospital, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Purpose: Pelvic recurrent aft er radiotherapy of cervical cancer was diffi cult to treat. Th e implantation of radioactive 125I seeds was suitable for recurrent patients aft er radiotherapy. Th erefore, we evaluated the effi cacy of radioactive 125I seeds implantation for pelvic recurrent cervical cancer aft er radiotherapy. Th e dosimetric parameters aff ecting outcome were further analyzed to guidance therapy. Methods: A retrospective analysis was made with pelvic recurrent cervical cancer aft er radiotherapy from July 2005 to October 2015 in our hospital with 125I seeds implantation, under ultrasound or CT guidance. Treatment planning was performed before implantation to estimate the number, activity of the seeds. Th e seeds numbers ranged from 10-140 with a median numbers of 62.5 and the activity of seeds ranged from 0.5-0.8 mCi with a median activity of 0.7 mCi. Dosimetric verifi cation was performed using CT scan immediately aft er 125I seeds implantation. D90, D100, V100, V150and V200 was evaluated in postoperative plan. Th e Kaplan-Meier method was used to calculate the local progression free survival (LPFS) rate and overall survival (OS) rate. Th e Log-rank test and Cox regression were used for univariate and multivariate analysis. Results: All of the 36 patients received pelvic radiotherapy previously, 13.88%(5/36) of the patients received re-irradiation. Th e median dose of cumulative radiotherapy was 56 (42-107) Gy EQD2. Th e interval time of the last radiotherapy to 125I implantation was 12 (2-60) months. 15 cases were central recurrence (41.67%, 15/36), and 21 cases were pelvic wall recurrence (58.33%, 21/36). Th e median follow-up time was 11.5 months (2-30 months). Vaginal fi stula occurred in 1 case. No other severe adverse eff ects. Th e downgrade rate of pain was 79.2% (19/24). Th e short-term local control rate was 88.9% (32/36). 1-year and 2-year local progression-free survival (LPFS) rate were 34.9% and 20%, respectively. 1-year and 2-year OS rate were 52% and 19.6%, respectively. Multivariate analysis showed that the location of the recurrence volume of lesion and D90 was signifi cantly related to LPFS (P<0.05). And the location of the recurrence was also signifi cantly related to OS (P<0.05). 33 cases were entered in dosimetric analysis. D90 was 128.5±47.4 Gy, D100 was 50.4±23.7 Gy, and V100 was 86.7%±12.9%. Univariate analysis showed that D100, D90, V100 were signifi cantly associated with LPFS (P<0.05). D90>105 Gy and <105 Gy 1-year LPFS were 53.3% and 0% (P<0.05), respectively. D100>55 Gy and <55 Gy, 1-year LPFS were 49.2% and 15.8% (P<0.05) respectively. V100>91% and <91%, 1-year LPFS were 55% and 15.6% (P<0.05), respectively. Multivariate analysis showed D100 was the independent factors. Conclusions: Radioactive 125I seeds implantation was a safe, eff ective salvage treatment for pelvic recurrent cervical cancer aft er radiotherapy. It could relieve the pain for patients undergone multiple treatment aft er relapse. 125I radioactive seed implantation was recommended for patients with recurrent in pelvic wall, compared with recurrent in central pelvic. D100>55Gy or D90>105Gy or V100>91% could signifi cantly improve the local control.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Qu Ang”